Source: International Congress 2019 – Clinical implications of asthma management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Mori (Sagamihara, Japan), S. Kouyama (Sagamihara, Japan), M. Yamaguci (Sagamihara, Japan), C. Kumitani (Sagamihara, Japan), N. Fujita (Sagamihara, Japan), M. Iwata (Sagamihara, Japan), K. Nagayama (Sagamihara, Japan), K. Ryu (Sagamihara, Japan), Y. Nakamura (Sagamihara, Japan), Y. Tomita (Sagamihara, Japan), Y. Hamada (Sagamihara, Japan), H. Hayashi (Sagamihara, Japan), K. Watai (Sagamihara, Japan), Y. Kamide (Sagamihara, Japan), K. Sekiya (Sagamihara, Japan), Y. Fukutomi (Sagamihara, Japan), M. Taniguchi (Sagamihara, Japan), T. Shimoda (Fukuoka, Japan), H. Odashima (Fukuoka, Japan), C. Motomura (Fukuoka, Japan), T. Fujisawa (Tsu, Japan), M. Nagao (Tsu, Japan), S. Shoji (Kiyose, Japan), O. Nobuharu (Kiyose, Japan), Y. Tanimoto (Okayama, Japan), T. Hasegawa (Kobe, Japan), T. Yoshida (Kobe, Japan), R. Kishikawa (Fukuoka, Japan). Simultaneous analysis of sputum and serum biomarkers in adult asthma. 5035

Member's Comments

No comment yet.

Related content which might interest you: Late-breaking abstract: Repeated analysis of alpha-1-antitrypsin concentrations in sputum, lavage and serum of smokers with and without COPD Source: Annual Congress 2011 - Cell biology of lung disease Year: 2011 Serum ECP in comparison to sputum ECP measurements in symptomatic and asymptomatic subjects with asthma Source: Eur Respir J 2001; 18: Suppl. 33, 335s Year: 2001 Proteomic derived biomarkers for COPD are present in induced sputum Source: Eur Respir J 2005; 26: Suppl. 49, 439s Year: 2005 Role of sputum eosinophil levels in the assessment of asthma treatment Source: Eur Respir J 2004; 24: Suppl. 48, 579s Year: 2004 Validation of sputum supernatant biomarker assays in stable and exacerbating COPD subjects Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Increased serum endotoxin levels as biomarker in acute exacerbations of COPD. Source: International Congress 2018 – Biomarkers of COPD Year: 2018 Differences in plasma and sputum biomarkers between COPD and COPD–asthma overlap Source: Eur Respir J 2014; 43: 421-429 Year: 2013 Comparison of blood and sputum analysis in evaluation of eosinophilic COPD Source: International Congress 2019 – Airway diseases and blood cells Year: 2019 Cross-sectional evaluation of serum and sputum calprotectin in bronchiectasis disease monitoring Source: International Congress 2019 – Bronchiectasis Year: 2019 Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes Source: Eur Respir J 2015; 46: 688-696 Year: 2015 Increased activin-a expression in serum, BAL and bronchial tissue of asthmatic patients Source: Annual Congress 2009 - Novel approaches in asthma Year: 2009 Proteomic analysis of sputum from adults with cystic fibrosis and COPD: identification of potential biomarkers for disease monitoring Source: Eur Respir J 2006; 28: Suppl. 50, 152s Year: 2006 Role of blood neutrophilia as a biomarker in asthma Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 High sputum ECP levels detect functional impairment in asthma better than sputum eosinophils Source: Annual Congress 2010 - Induced sputum in relation: a fresh look on phenotyping and monitoring Year: 2010 Pharmacodynamic effect of benralizumab on blood basophils and serum biomarkers in adults with COPD with sputum eosinophilia Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Routine blood test biomarkers and their association with exacerbations in COPD Source: International Congress 2019 – Airway diseases and blood cells Year: 2019 The influence of the COPD exacerbation treatment on the MMP-9 concentration in serum, induced sputum and BAL Source: Eur Respir J 2005; 26: Suppl. 49, 298s Year: 2005 Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap Source: Annual Congress 2013 –Is it really asthma? Year: 2013 Serum G-CSF is a non-invasive biomarker classifying bacterial/neutrophilic COPD exacerbations Source: Virtual Congress 2020 – Phenotypes of asthma and COPD Year: 2020 Simultaneous analysis of clinical markers for predicting increased lung function fluctability in stable asthma Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012